Preclinical News and Research

RSS

CUMC researchers clarify three fundamental issues about Alzheimer's disease

Using high-resolution functional MRI imaging in patients with Alzheimer's disease and in mouse models of the disease, Columbia University Medical Center researchers have clarified three fundamental issues about Alzheimer's: where it starts, why it starts there, and how it spreads. In addition to advancing understanding of Alzheimer's, the findings could improve early detection of the disease, when drugs may be most effective.

22 Dec 2013

ORIX USA Health partners with TGen and TD2 to support Arizona's biomedical economy

ORIX USA Health and Life Sciences has completed an investment into Translational Drug Development (TD2) through the purchase of equity from the Translational Genomics Research Institute (TGen).

20 Dec 2013

Study reveals that global pricing teams outsource 50% of activities

On average, global pricing teams outsource 50% of activities that they budget for, according to study of pharmaceutical pricing teams by Cutting Edge Information.

20 Dec 2013

New research assesses nanomedicine-based approaches for treating cancer

As cancer maintains its standing as the second leading cause of death in the U.S., researchers have continued their quest for safer and more effective treatments. Among the most promising advances has been the rise of nanomedicine, the application of tiny materials and devices whose sizes are measured in the billionths of a meter to detect, diagnose and treat disease.

20 Dec 2013

Merck and CNIO sign agreement to collaborate in area of cancer drug development

The Spanish National Cancer Research Centre (CNIO) and the German chemical and pharmaceutical company Merck today signed an agreement in Madrid to collaborate in the area of cancer drug development.

19 Dec 2013

Helsinn, Mundipharma sign distribution and license agreement for investigational therapy

Helsinn and Mundipharma announce the signature of a new, exclusive license and distribution agreement, covering China, Hong Kong and Macao, for netupitant-palonosetron fixed dose combination, a Helsinn product under development for the treatment of chemotherapy-induced nausea and vomiting.

19 Dec 2013

LSDF announces research and development grants to commercialize health-related technologies

The Life Sciences Discovery Fund (LSDF) today announced $1.1 million in five Proof of Concept grants to Washington for-profit and non-profit organizations to foster the translation of health-related products from the laboratory into the commercial marketplace.

19 Dec 2013

TGen, Nemucore, and Barrow collaboration aims for new drugs to treat glioblastoma

The Ben & Catherine Ivy Foundation today announced a $3 million grant to the Translational Genomics Research Institute (TGen), Nemucore Medical Innovations Inc., and Barrow Neurological Institute at St. Joseph's Hospital and Medical Center to help fund significant brain tumor research in Arizona.

18 Dec 2013

Merck signs license agreement with CNIO for cancer drug development

Merck Serono, the biopharmaceutical division of Merck, today announced that a license agreement has been signed with the Spanish National Cancer Research Centre in Madrid in the area of cancer drug development. The global agreement will build upon CNIO research discoveries to encourage the development and commercialization of new compounds in the field of oncology.

18 Dec 2013

BioLineRx enrolls first patient in BL-7010 Phase 1/2 trial for treatment of celiac disease

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today enrollment of the first patient in a Phase 1/2 trial of BL-7010, for the treatment of celiac disease. The first patient was enrolled at Tampere Hospital in Finland, a world-leading site for celiac disease research. Results are expected in mid-2014.

18 Dec 2013

New projects advance treatments for radiation syndrome, cardiac arrest-induced brain injury and rare blood disorder

The National Institutes of Health today has launched three pre-clinical projects to advance potential new treatments for acute radiation syndrome, brain injury following cardiac arrest and a rare blood disorder called beta thalassemia.

17 Dec 2013

Researchers use ATX-Red AR-2 as new imaging agent to illuminate tumors

Researchers from Echelon Biosciences, Inc. and collaborators from the University of Utah report the use of ATX-Red AR-2 as a new imaging agent that effectively illuminates tumors.

17 Dec 2013

Preclinical data shows BGB324 as potential treatment option for Chronic Myeloid Leukemia

BerGenBio AS, an oncology biopharmaceutical company, announces that preclinical data demonstrating that BGB324 has potential application as a novel treatment for Chronic Myeloid Leukemia, was presented in a poster at the Annual Meeting of the American Society of Hematology, which took place on December 7-10, 2013.

17 Dec 2013

Atara Biotherapeutics secures $38.5M in initial closings under Series B financing

Atara Biotherapeutics, Inc., a drug development company with a focus on innovative therapies for patients with debilitating diseases, announced today that it has secured $38.5 million in initial closings under its Series B financing. In this round, investors Amgen Ventures, Celgene Corporation, and EcoR1 Capital, joined existing investors Alexandria Venture Investments, DAG Ventures, Domain Associates, and Kleiner Perkins Caufield & Byers.

17 Dec 2013

BioLineRx reports promising initial results from Phase 2 trial of BL-8040 in AML patients

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today promising initial results for its BL-8040 drug candidate in a Phase 2 clinical trial for patients with relapsed or refractory acute myeloid leukemia (AML).

16 Dec 2013

Stem cell technology: an interview with Professor Igor Slukvin, University of Wisconsin-Madison and scientific founder of CDI and Cynata

Stem cells have a potential to develop into multiple cell types and divide without limit to replenish cells in human body throughout the life of individual.

16 Dec 2013

Cetuximab fails in second-line combination for recurrent NSCLC

Results from a phase III trial indicate that cetuximab should not be given alongside chemotherapy in patients with recurrent non-small-cell lung cancer after platinum-based therapy.

13 Dec 2013

Study: Antisense drugs show activity in wide range of tissues and organs

Antisense therapeutics, a class of drugs comprised of short nucleic acid sequences, can target a dysfunctional gene and silence its activity. A new study has shown that antisense drugs delivered systemically show activity in a wide range of tissues and organs, supporting their broad therapeutic potential in many disease indications, as described in an article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

13 Dec 2013

Z-endoxifen may provide better treatment for women with estrogen positive breast cancer

A Phase I trial of endoxifen, an active metabolite of the cancer drug tamoxifen, indicates that the experimental drug is safe, with early evidence for anti-tumor activity, a Mayo Clinic study has found. The findings indicate that Z-endoxifen, co-developed by Mayo Clinic Cancer Center and the National Cancer Institute, may provide a new and better treatment for some women with estrogen positive breast cancer and, in particular, for those women who do not respond to tamoxifen and aromatase inhibitors.

13 Dec 2013

Retrophin to acquire privately-held company, Kyalin Biosciences

Retrophin, Inc. today announced that it will acquire privately-held Kyalin Biosciences, Inc., an early-stage company based in San Diego, CA, that is developing therapies targeting the core symptoms of autism and related conditions.

12 Dec 2013

Preclinical News and Research

CUMC researchers clarify three fundamental issues about Alzheimer's disease

ORIX USA Health partners with TGen and TD2 to support Arizona's biomedical economy

Study reveals that global pricing teams outsource 50% of activities

New research assesses nanomedicine-based approaches for treating cancer

Merck and CNIO sign agreement to collaborate in area of cancer drug development

Helsinn, Mundipharma sign distribution and license agreement for investigational therapy

LSDF announces research and development grants to commercialize health-related technologies

TGen, Nemucore, and Barrow collaboration aims for new drugs to treat glioblastoma

Merck signs license agreement with CNIO for cancer drug development

BioLineRx enrolls first patient in BL-7010 Phase 1/2 trial for treatment of celiac disease

New projects advance treatments for radiation syndrome, cardiac arrest-induced brain injury and rare blood disorder

Researchers use ATX-Red AR-2 as new imaging agent to illuminate tumors

Preclinical data shows BGB324 as potential treatment option for Chronic Myeloid Leukemia

Atara Biotherapeutics secures $38.5M in initial closings under Series B financing

BioLineRx reports promising initial results from Phase 2 trial of BL-8040 in AML patients

Stem cell technology: an interview with Professor Igor Slukvin, University of Wisconsin-Madison and scientific founder of CDI and Cynata

Cetuximab fails in second-line combination for recurrent NSCLC

Study: Antisense drugs show activity in wide range of tissues and organs

Z-endoxifen may provide better treatment for women with estrogen positive breast cancer

Retrophin to acquire privately-held company, Kyalin Biosciences

Event guide: 4th LNP Formulation & Process Development Summit eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics